{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T05:33:46Z","timestamp":1761802426330,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007605","name":"Aarhus Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007605","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R167-A11045\u201317-S2"],"award-info":[{"award-number":["R167-A11045\u201317-S2"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.canep.2022.102311","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T01:27:38Z","timestamp":1670549258000},"page":"102311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Risk of primary haematologic cancers following incident non-metastatic breast cancer: A Danish population-based cohort study"],"prefix":"10.1016","volume":"82","author":[{"given":"Cathrine F.","family":"Hjorth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00f3ra K.","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia","family":"Schapira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark R.","family":"Cullen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik T.","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9738-2284","authenticated-orcid":false,"given":"Deirdre","family":"Cronin-Fenton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canep.2022.102311_bib1","doi-asserted-by":"crossref","unstructured":"Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin [Internet]. 2020 [cited 2021 Mar 15];n\/a(n\/a). Available from: \u3008https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/abs\/10.3322\/caac.21660\u3009.","DOI":"10.3322\/caac.21660"},{"key":"10.1016\/j.canep.2022.102311_bib2","unstructured":"American Cancer Society. Survival Rates for Breast Cancer [Internet]. 2021 [cited 2021 Mar 15]. Available from: \u3008https:\/\/www.cancer.org\/cancer\/breast-cancer\/understanding-a-breast-cancer-diagnosis\/breast-cancer-survival-rates.html\u3009."},{"issue":"2","key":"10.1016\/j.canep.2022.102311_bib3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ijrobp.2012.09.001","article-title":"Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship","volume":"86","author":"Berrington de Gonzalez","year":"2013","journal-title":"Int. J. Radiat. Oncol."},{"issue":"3","key":"10.1016\/j.canep.2022.102311_bib4","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0360-3016(01)01665-0","article-title":"Second cancers after conservative surgery and radiation for stages I\u2013II breast cancer: identifying a subset of women at increased risk","volume":"51","author":"Fowble","year":"2001","journal-title":"Int. J. Radiat. Oncol."},{"issue":"5","key":"10.1016\/j.canep.2022.102311_bib5","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.ijrobp.2014.12.051","article-title":"Second malignancies after adjuvant radiation therapy for early stage breast cancer: is there increased risk with addition of regional radiation to local radiation?","volume":"91","author":"Hamilton","year":"2015","journal-title":"Int. J. Radiat. Oncol."},{"issue":"3","key":"10.1016\/j.canep.2022.102311_bib6","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.radonc.2016.08.017","article-title":"Risk of second non-breast cancer among patients treated with and without postoperative radiotherapy for primary breast cancer: a systematic review and meta-analysis of population-based studies including 522,739 patients","volume":"121","author":"Grantzau","year":"2016","journal-title":"Radiother. Oncol."},{"issue":"4","key":"10.1016\/j.canep.2022.102311_bib7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3816\/CBC.2003.n.032","article-title":"Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the national surgical adjuvant breast and bowel project experience","volume":"4","author":"Smith","year":"2003","journal-title":"Clin. Breast Cancer"},{"issue":"1","key":"10.1016\/j.canep.2022.102311_bib8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ygyno.2014.10.029","article-title":"Risk of second cancers cancer after a first primary breast cancer: a systematic review and meta-analysis","volume":"136","author":"Molina-Montes","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canep.2022.102311_bib9","doi-asserted-by":"crossref","unstructured":"Valentini C.G., Fianchi L., Voso M.T., Caira M., Leone G., Pagano L. Incidence of Acute Myeloid Leukemia after Breast Cancer. Mediterr J Hematol Infect Dis [Internet]. 2011 Dec 22 [cited 2019 Nov 5];3(1). Available from: \u3008https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3248346\/\u3009.","DOI":"10.4084\/mjhid.2011.069"},{"issue":"2","key":"10.1016\/j.canep.2022.102311_bib10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ijc.32259","article-title":"Incidence of second primary malignancy after breast cancer and related risk factors\u2014Is breast-conserving surgery safe? A nested case\u2013control study","volume":"146","author":"Li","year":"2020","journal-title":"Int. J. Cancer"},{"issue":"9","key":"10.1016\/j.canep.2022.102311_bib11","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1002\/ijc.21651","article-title":"Risk of second cancer among women with breast cancer","volume":"118","author":"Mellemkjaer","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.canep.2022.102311_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.7147","article-title":"Evaluation of the incidence of hematologic malignant neoplasms among breast cancer survivors in France","volume":"2","author":"Jabagi","year":"2019","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.canep.2022.102311_bib13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.canrad.2016.07.101","article-title":"Risks of second malignancies after breast cancer treatment: long-term results","volume":"21","author":"Bazire","year":"2017","journal-title":"Cancer\/Radiotherapie"},{"issue":"4","key":"10.1016\/j.canep.2022.102311_bib14","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/02841860801978921","article-title":"Risk of second primary cancer among patients with early operable breast cancer registered or randomised in Danish Breast Cancer cooperative Group (DBCG) protocols of the 77, 82 and 89 programmes during 1977\u20132001","volume":"47","author":"Andersson","year":"2008","journal-title":"Acta Oncol."},{"issue":"8","key":"10.1016\/j.canep.2022.102311_bib15","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s10147-019-01430-0","article-title":"Survival and chemotherapy-related risk of second primary malignancy in breast cancer patients: a SEER-based study","volume":"24","author":"Wei","year":"2019","journal-title":"Int. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.canep.2022.102311_bib16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/annonc\/mdn530","article-title":"Acute myeloid leukemia after breast cancer: a population-based comparison with hematological malignancies and other cancers","volume":"20","author":"Beadle","year":"2009","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.canep.2022.102311_bib17","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1200\/JCO.2013.54.6119","article-title":"Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience","volume":"33","author":"Wolff","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.canep.2022.102311_bib18","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1200\/JCO.20.00199","article-title":"Breast cancer: 45 years of research and progress","volume":"38","author":"Hortobagyi","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.canep.2022.102311_bib19","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1080\/02841860802059259","article-title":"The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise","volume":"47","author":"M\u00f8ller","year":"2008","journal-title":"Acta Oncol. Stock. Swed."},{"issue":"7","key":"10.1016\/j.canep.2022.102311_bib20","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3109\/0284186X.2011.602111","article-title":"TAXTOX \u2013 a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009","volume":"50","author":"Eckhoff","year":"2011","journal-title":"Acta Oncol."},{"issue":"4","key":"10.1016\/j.canep.2022.102311_bib21","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am. J. Epidemiol."},{"issue":"10","key":"10.1016\/j.canep.2022.102311_bib22","first-page":"1027","article-title":"How representative are the surveillance, epidemiology, and end results (SEER) program cancer data of the United States","volume":"15","author":"Merrill","year":"2004","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.canep.2022.102311_bib23","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2147\/CLEP.S179083","article-title":"The Danish health care system and epidemiological research: from health care contacts to database records","volume":"11","author":"Schmidt","year":"2019","journal-title":"Clin. Epidemiol."},{"issue":"8","key":"10.1016\/j.canep.2022.102311_bib24","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","article-title":"The Danish Civil Registration System as a tool in epidemiology","volume":"29","author":"Schmidt","year":"2014","journal-title":"Eur. J. Epidemiol."},{"issue":"4","key":"10.1016\/j.canep.2022.102311_bib25","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/02841860802056594","article-title":"Recurrence pattern and prognosis in low-risk breast cancer patients--data from the DBCG 89-A programme","volume":"47","author":"Christiansen","year":"2008","journal-title":"Acta Oncol. Stock. Swed."},{"issue":"4","key":"10.1016\/j.canep.2022.102311_bib26","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/00008469-200208000-00007","article-title":"Validity of breast cancer in the Danish Cancer Registry. A study based on clinical records from one county in Denmark","volume":"11","author":"Jensen","year":"2002","journal-title":"Eur. J. Cancer Prev."},{"issue":"7 Suppl","key":"10.1016\/j.canep.2022.102311_bib27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/1403494810393562","article-title":"The Danish cancer registry","volume":"39","author":"Gjerstorff","year":"2011","journal-title":"Scand. J. Public Health"},{"issue":"5","key":"10.1016\/j.canep.2022.102311_bib28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"10.1016\/j.canep.2022.102311_bib29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/CLEP.S9908","article-title":"Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank","volume":"2","author":"Erichsen","year":"2010","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.canep.2022.102311_bib30","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.2147\/CLEP.S164456","article-title":"Sampling strategies for selecting general population comparison cohorts","volume":"10","author":"Heide-J\u00f8rgensen","year":"2018","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.canep.2022.102311_bib31","doi-asserted-by":"crossref","unstructured":"Jabagi M.J., Vey N., Goncalves A., Le Tri T., Zureik M., Dray-Spira R. Risk of secondary hematologic malignancies associated with breast cancer chemotherapy and G-CSF support: A nationwide population-based cohort. Int J Cancer. 2020 Jul 19.","DOI":"10.1002\/ijc.33216"},{"issue":"3","key":"10.1016\/j.canep.2022.102311_bib32","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1200\/JCO.2006.05.9048","article-title":"Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer","volume":"25","author":"Le Deley","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.canep.2022.102311_bib33","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3390\/cancers11101463","article-title":"Risk of hematologic malignant neoplasms after postoperative treatment of breast cancer","volume":"11","author":"Jabagi","year":"2019","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.canep.2022.102311_bib34","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1053\/j.seminoncol.2008.04.012","article-title":"Therapy-related myeloid leukemia","volume":"35","author":"Godley","year":"2008","journal-title":"Semin. Oncol."},{"issue":"1","key":"10.1016\/j.canep.2022.102311_bib35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jnci\/djz157","article-title":"Evaluating clonal hematopoiesis in tumor-infiltrating leukocytes in breast cancer and secondary hematologic malignancies","volume":"112","author":"Comen","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canep.2022.102311_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103607","article-title":"Diagnosis and treatment of therapy-related acute myeloid leukemia","volume":"171","author":"Strickland","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"25","key":"10.1016\/j.canep.2022.102311_bib37","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1200\/JCO.2007.12.0832","article-title":"Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk","volume":"25","author":"Patt","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.canep.2022.102311_bib38","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1158\/1055-9965.EPI-11-0009","article-title":"Risk of primary non-breast cancer after female breast cancer by age at diagnosis","volume":"20","author":"Mellemkj\u00e6r","year":"2011","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.canep.2022.102311_bib39","unstructured":"Chronic Lymphocytic Leukemia Treatment (PDQ\u00ae)\u2013Patient Version - National Cancer Institute [Internet]. 2021 [cited 2021 May 6]. Available from: \u3008https:\/\/www.cancer.gov\/types\/leukemia\/patient\/cll-treatment-pdq\u3009."},{"issue":"9","key":"10.1016\/j.canep.2022.102311_bib40","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/sj.bjc.6603404","article-title":"Family history of breast cancer and young age at diagnosis of breast cancer increase risk of second primary malignancies in women: a population-based cohort study","volume":"95","author":"Prochazka","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canep.2022.102311_bib41","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/CLEP.S49773","article-title":"Validity of the Danish National Registry of Patients for chemotherapy reporting among colorectal cancer patients is high","volume":"5","author":"Lund","year":"2013","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.canep.2022.102311_bib42","unstructured":"Danish Breast Cancer Group [Internet]. DBCG protocols, overview [Internet]. Available from: \u3008https:\/\/www.dbcg.dk\/PDF\/DBCG_2014_protokoller_oversigt_01.08.2014.pdf\u3009."},{"key":"10.1016\/j.canep.2022.102311_bib43","unstructured":"The Cancer Atlas. Cancer Survivorship Worldwide [Internet]. The Cancer Atlas. [cited 2019 Feb 15]. Available from: \u3008http:\/\/canceratlas.cancer.org\/the-burden\/cancer-survivorship\/\u3009."}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782122002168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782122002168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T05:30:56Z","timestamp":1761802256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782122002168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":43,"alternative-id":["S1877782122002168"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2022.102311","relation":{},"ISSN":["1877-7821"],"issn-type":[{"type":"print","value":"1877-7821"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of primary haematologic cancers following incident non-metastatic breast cancer: A Danish population-based cohort study","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2022.102311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102311"}}